INTRODUCTION: USEFULNESS AND LIMITATIONS OF TYPICAL ANTIPSYCHOTICS
The pnmary rationale to test atypical antipsychotics in bipolar disorder was the extensive clinical experience and established usefulness of classical antipsychotics in manic disorder. Due to their rapid sedative and antipsychotic effect these drugs proved to be useful in psychotic, agitated and hostile patients. 1 .specially in those patients not willing to take medication at all, the availability of intramuscular formulations was helptul. However, their disadvantages are obvious. A significant short-coming is the limited, if at all, efficacy in prophylaxis (Ahlfors et al, 1981; Ksparon et al, 1986) .
While treating mania with a classical antipsychotic drug, the clinician is afraid of the emergence of depressive symptoms (Harrow et al, 1994) . The major disadvantages are the numerous side effects ranging from anticholinergic and cognitive side effects to typical extrapyramidal syndromes (IZPS) and, for worst, tardive dyskinesia. In up to 80% of bipolar patients acute HI'S have been observed (Briine, 1999 ) whereas tardive dyskinesias are described in up to 35% of bipolar patients with long-term neuroleptic treatment (Mukhcrjee et al, 1986 ).
Nevertheless, typical antipsychotics arc widely used in most parts of the world. In Germany, a census of the "Arzneimittcluberwachungin der Psychiatrie" (AMUP) Bayern, held in 1998, covered 275 acutely manic patients in different Bavarian state hospitals.
In this study, an extensive use of typical antipsychotics has been noted. Of all manic patients, 83% received antipsychotics (Griinze and Dobmeier, 2002) . In addition to this evidence, of clinical use, some controlled studies also support the efficacy of classical antipsychotics. As of 1 999, 9 controlled studies comparing haloperidol to different standards have been published. In most of these, haloperidol was found to either beat the comparators or have at least equal efficacy (Griinze, 1999) . None of these trials, however, had a placebo arm.
Efficacy of haloperidol against placebo has only been shown recently in one monotherapy study (unpublished data, Astra Zeneca, on file) and one add-on study (Sachs et al, 2002b) . Haloperidol, used as a comparator, was superior to placebo in both studies.
Typical antipsychotics appear to be of special usefulness in severely manic and psychotic patients. The Northwick Park study (Johnstone et al, 1988) , which compared pimozide, lithium and placebo in 120 patients with functional psychosis found that pimozide was effective both for mania and psychotic symptoms, whereas lithium was effective on elevated mood only. With the broadening of the bipolar spectrum, psychotic symptoms have been accommodated fairly well within the scope of bipolar disorder as long as they do not dominate the clinical picture and overshadow the mood symptoms. Thus, a considerably higher number of patients will be diagnosed as bipolar disorder with psychotic symptoms, demanding treatment tliat is different from established mood stabilizers such as lithium. Atypical antipsychotics, combining probably the broader effectiveness of classical antipsychotics with improved tolerability may thus be appropriate for this new challenge.
MONOTHERAPY WITH ATYPICAL ANTIPSYCHOTICS

IN BLPOLAR DISORDER
Derivatives of clozapine:
Olanzapine and quetiapine Clozapine can be considered as the (10) father of atypical antipsychotics. Numerous case reports and several small investigatorinitiated trials support its antimanic as well as mild antidepressive and good prophylactic efficacy in bipolar patients (Frye et al, 1998) Olanzapine has shown significant superiority over placebo in two double-blind placebo-controlled monotherapy studies (Tohen et al, 1999; Tohen ct al, 2000) . These studies had a duration of three and four weeks, respectively, applying a maximum dose of 20 mg/day of olanzapine. It is of interest, that especially in the 4-week study (Tohen et al, 2000) a relatively large number of patients with mixed states (43%) had been included. In both studies, more than 50% of patients showed psychotic features also. It is of clinical importance that the improvement, as measured by the fall in the Young Mania Rating Scale (YMRS) scores, was not different in psychotic and nonpsychotic manic patients. Thus, improvement \ cannot be explained as a function of treatment of psychotic symptoms alone as, obviously, there are genuine effects on mood. No difference in efficacy measures could be found when coinparing patients with and without rapid cycling (Tohen ct al. 2000) . In the same vein, patients with The overall outcome after eight weeks was similar for quctiapine and haloperidol.
Haloperidol showed a slightly faster onset of action whereas quetiapine was clearly better tolerated by the patients. For a more detailed review of these trials, one has to wait for the data to be published.
Ziprasidone and risperidone
These two atypical antipsychotics define themselves mainly by a very pronounced serotonergic component of action, both having a similar occupancy profile for die 5-HT,A receptor. Ziprasidone has additional occupancy of the 5-H^A receptor. The dopaminergic D, receptor affinity is relatively stronger than with clozapine, quctiapine or olanzapine, which may also result in higher incidence of EPS when overdosed.
Ziprasidone was tested for antimanic efficacy in a double-blind placebo-controlled multicentre study for the duration of three weeks, including 197 patients. The primary outcome parameter was the Mania Rating Scale, which consists of 10 items from the SRDS-C. Thus, this study had a design that was very similar to the pivotal study by Bowden et al (1994) , comparing valproate against lithium and placebo. Ziprasidone was significantly superior to placebo starting from day 2 until day 21, the endpoint of the study (p<0.01). In the PANSS positive subscale, the secondary outcome parameter, ziprasidone also showed a significant effect on psychotic symptoms in these manic patients.
For risperidone, double-blind placebocontrolled monotherapy trials have been conducted but, as with quctiapine, are not published so far. We arc aware of two trials and both showed a significant antimanic response with risperidone as compared to the placebo arm (Janssen-Cilag, data on file).
In one of these studies, conducted in India, a mean reduction of 21 points in the YMRS was observed, an antimanic response hardly ever seen in any controlled Phase III trial.
However, approximately 50% of the patients had EPS also. One may argue that in general, the india patients have a lower bodyweight and that they might have been receiving a much higher dose as compared to US and European trials.
Aripiprazole
The 
THE USEFULNESS OF ATYPICAL ANTIPSYCHOTICS IN COMBINATION TREATMENT
Monotherapy trials arc needed to show unambiguous efficacy of a drug, even thugh combination treatment is the clinical reality, lor example, looking prospectively into the treatment of 258 patients of the Stanley foundation bipolar Network, it was noted that patients receive an average of 4.1 medications for mood stabilisation (Post ct al, 2002) . This trend towards combination treatment has also been demonstrated in other studies (l'rvc et al, 2000) , including our own, conducted in the outpatient clinic in Munich as a part of the Stanley foundation Bipolar Network (Dittmann et al, 2002) . I lowcvcr, until recently only a few controlled tnals were designed to test efficacy in combination treatment. Now we have three pivotal trials for olanzapine, risperidone and c|uctiapinc looking into this issue.
In the study of Tohen et al. (2002b) patients were treated with cither valproate or lithium for acute mania. Those not showing sufficient response after three weeks were then randomised and treated in a double-blind fashion with either olanzapine (n = 220) or placebo (n=114) as an add-on. Olanzapine treated patients had a significant better outcome reflected by the YMRS. total For quetiapine, two studies using an addon design have been presented recendy. In a stud) by Sachs and colleagues (Sachs et al., 2002a) quetiapine was used as an adjunct treatment to lithium or valproate for 21 days in acutely manic patients. For the primary outcome criteria (YMRS) as well as for several secondary outcome criteria, including the CG1-BP, a significant advantage of quetiapine co-administration was observed. The incidence of adverse events was generally low and discontinuation due to these events was similar in both groups.
The other study by Del Bello ct al (2002) tested the usefulness of quetiapine add-oii to valproate compared to placebo add-on for the treatment of acute mania in adolescents. Thirty patients were included in the study, and again the YMRS response rate was significantly greater in the valproate plus quetiapine group than in the valproate plus placebo group (87% versus 53%). Side effects were again scarce and not different from the placebo group. These findings arc of special importance as predominant symptoms of mania in adolescents arc often psychotic features, mixed states and rapid cycling (Carlson and Kashani, 2002; Findling et al, 2001) , and so far few studies looked systematically into response rates and tolcrability in younger patients.
Risperidone was also tested in two trials, one conducted in the US and one internationally, for its efficacy in manic or mixed episodes, applying an add-on design to previous mood stabilizer treatment. In the US study (Sachs et al. 2002b ) lithium or valproate were allowed as mood stabilizers, whereas in the international study, carbamazepine could also be used. In addition, the US study had a halopcridol arm as an internal comparator. In the US study, both haloperidol and risperidone was statistically significantly superior to the addon placebo arm. Significance for risperidone was missed in the international study at first analysis. When excluding those patients who had been on carbamazepine, however, the international study was also able to show a significant advantage of risperidone add-on treatment compared to placebo (Yatham, 2000) .
From this study, it becomes obvious that combination treatment, including those with atypical antipsychotics, has to be conducted good skill keeping in mind the possibility of drug-drug interactions, for example on the level of the cytochrome P450. Both the US and the international study showed comparable efficacy for risperidone in patients exhibiting psychotic features or not. Side effects of risperidone were generally low, especially compared to haloperidol where a significantly higher incidence of EPS was observed.
In general, there seems to be a consensus that the side effects with atypical antipsychotics are lower in comparison to typical antipsychotics. This is an important issue as it may determine patients' compliance. Weight gain is clearly a disadvantage of clozapine and olanzapine and less pronounced in risperidone and quetiapine, whereas ziprasidone is almost weight neutral. Weight gain is also associated with the increased risk of cardiovascular mortality, which is 1.6 rimes higher in treated bipolar patients and 2.1 times higher in untreated bipolar patients, compared to the general population (Angst ct al, 2002) . Thus, when choosing the appropriate atypical antipsychotic for treating bipolar patients, this issue should be kept in mind and discussed openly with the patient.
Effects of olanzapine on depressive symptoms in mixed patients have alreadybeen described previously for the monotherapy trials. In a recent combination treatment trial, olanzapine was compared against placebo and a combination of olanzapine and fluoxetine for the treatment of psychotic depression (Dube et al. 2002) . In this double-blind 8 week trial, both olanzapine and the combination of olanzapine and fluoxetine separated significantly from placebo response in the Montgomery Asberg Depression Rating Scale (12) (MADRS), the primary outcome criterion. However, the time to response was clearly shortened by the combination of olanzapine and fluoxetine compared to both placebo and olanzapine monotherapy. Preliminary data for risperidone (Canuso, 2003) also support an antidepressant component of action.
As suicidally obviously threatens bipolar depressed patients (Bottlender et al, 2000) , it is of highly relevant clinically that better and faster acting treatments are developed for depressive episodes in bipolar patients. In this context, it is of interest that a recent study by Meltzer and colleagues (Meltzer et al, 2003) demonstrated antisuicidal effects of clozapine in schizophrenic and schizoaffective patients.
MAINTENANCE TREATMENT: FIRST EXPERIENCES WITH ATYPICAL ANTIPSYCHOTICS
Data on long-term efficacy of atypical antipsychotics in bipolar patients are still very limited. In a six month open study, 541 patients received risperidone as an add-on treatment to previous mood stabiliser treatment (Victa et al, 2001 ). Both the mean YMRS and HAMD scores declined rapidly and remained on a low level in these bipolar I, bipolar II, or schizoaffective patients.
For olanzapine, three controlled studies, one against placebo and two against comparators (valproate and lithium) furnish first evidence for a long-term prophylactic effect.
In the placebo controlled study (Tohen, 2002) , patients in acute manic or mixed episodes of bipolar I disorder were treated with open-labelled olanzapine for a period of 6-12 weeks. Those achieving symptomatic remission (YMRS <=12 and HAMD-21 <=8) were randomized to olanzapine (N=225) (5-20 mg/d) or placebo (N=136) for another 52 weeks of double-blind treatment. Whereas 80.1% of patients randomized to placebo suffered from at least one new episode during the following year, only 46.7 % of patients on olanzapine relapsed (p<0.001). Extending on the previously cited acute mania trial comparing olanzapine and valproate, Tohen et al (2001) conducted a 47 week continuation, doubleblind parallel group trial in those patients who responded to either valproate or olanzapine in acute mania. There was no significant difference in the number of manic relapses or in the median time to relapse between olanzapine and valproate treatments, however, there was a tendency to have fewer fresh manic episodes with olanzapine.
The prophylactic antimanic efficacy of olanzapine is also supported by a recently presented 12 months double blind trial comparing olanzapine and lithium in patients who were euthymic at the beginning of the study (Tohen et al, 2002c) . Olanzapine outperformed lithium both in the survival analysis and in the percentage of patients who relapsed into mania. No difference was observed with respect to the percentage of patients who experienced a depressive relapse. Thus, olanzapine may constitute an alternative to lithium in prophylactic treatment for patients who have predominandy manic episodes. If preventing new depressed episodes is of similar clinical importance, combination therapies, e.g. with lamotrigine, should be considered (Goodwin et al, 2002) .
CONCLUSIONS
Atypical antipsychotics are an emerging treatment for bipolar patients as summarized in the Table 1 . Both controlled and real world studies with risperidone, olanzapine, ziprasidone, quetiapine and aripiprazole showed efficacy in treating acute mania. Atypical antipsychotics seem also to improve depressive symptoms or at least do not worsen depression as conventional antipsychotics may do. Controlled data, though preliminary in nature, also support prophylactic efficacy especially for olanzapine 
